GE Healthcare will exclusively distribute DiscoverX's HitHunter cAMP enzyme fragment complementation-based assays worldwide, the companies said this week.

The deal also expands GE Healthcare's exclusive rights to market the rest of DiscoverX' HitHunter product portfolio to regions outside of North America and Europe, a DiscoverX executive said.

The deal is a significant marketing shot in the arm for DiscoverX's flagship product line, and it also allows DiscoverX to focus its resources more on scientific collaborations, R&D, and product development.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.